This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.
Here is a sample of this item:
by Stockwatch Business Reporter
The TSX Venture Exchange closed up 12.49 points to 743.26 Wednesday. Salim Ansari's first capital pool shell,
Nurcapital Corporation Ltd. (NCL: suspended), plans to acquire
a biotech investment firm called Green Sky Labs Inc. for the shell's qualifying transaction.
The shell will roll back 1 for 3.65, leaving it with 881,481 shares issued, then issue 100,460,538 shares to its target's shareholders.
Green Sky uses the word "biotech," but in more specific and trendy terms, it means COVID-19 and cannabis. The company holds interests in five businesses (or, more accurately in some cases, business plans). First, there is Next Health Inc., operating as My Next Health. This company is working on a genetics-based risk assessment app for COVID-19. So far, there is a COVID-19 risk assessment questionnaire on the company's website. My Next Health also has a chronic pain management app called My Pain Sensei, but it does not hype this app all that much. It puts more effort into talking up genomics and artificial intelligence in connection with its COVID-19 app under development.
The remainder is available to Stockwatch subscribers.
© 2020 Canjex Publishing Ltd. All rights reserved.